Exploring determinants of psoriasis patients’ treatment choices: a discrete-choice experiment study in the United States and Germany

References

• Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80:1029–1072.
   PubMed Web of Science ®Google Scholar
• Fairchild AO, Reed SD, Johnson FR, Anglin G, et al. What is clearance worth? Patients' stated risk tolerance for psoriasis treatments. J Dermatolog Treat. 2017;28:709–715.
   PubMed Web of Science ®Google Scholar
• Ashcroft DM, Seston E, Griffiths CE. Trade-offs between the benefits and risks of drug treatment for psoriasis: a discrete choice experiment with U.K. dermatologists. Br J Dermatol. 2006;155:1236–1241.
   PubMed Web of Science ®Google Scholar
• Kjaer T, Bech M, Gyrd-Hansen D, et al. Ordering effect and price sensitivity in discrete choice experiments: need we worry? Health Econ. 2006;15:1217–1228.
   PubMed Web of Science ®Google Scholar
• Kauf TL, Yang JC, Kimball AB, et al. Psoriasis patients' willingness to accept side-effect risks for improved treatment efficacy. J Dermatolog Treat. 2015;26:507–513.
   PubMed Web of Science ®Google Scholar
• Gonzalez JM, Johnson FR, McAteer H, et al. Comparing preferences for outcomes of psoriasis treatments among patients and dermatologists in the U.K.: results from a discrete-choice experiment. Br J Dermatol. 2017;176:777–785.
   PubMed Web of Science ®Google Scholar
• Schaarschmidt ML, Herr R, Gutknecht M, et al. Patients' and physicians' preferences for systemic psoriasis treatments: a nationwide comparative discrete choice experiment (PsoCompare). Acta Derm Venereol. 2018;98:200–205.
   PubMed Web of Science ®Google Scholar
• Sain N, Willems D, Charokopou M, et al. The importance of understanding patient and physician preferences for psoriasis treatment characteristics: a systematic review of discrete-choice experiments. Curr Med Res Opin. 2020;36;1257–1275.
   PubMed Web of Science ®Google Scholar
• Boeri M, Saure D, Schacht A, et al. Modeling heterogeneity in patients' preferences for psoriasis treatments in a multicountry study: a comparison between random-parameters logit and latent class approaches. Pharmacoeconomics. 2020;38:593–606.
   PubMed Web of Science ®Google Scholar
• Christophers E, Griffiths CE, Gaitanis G, et al. The unmet treatment need for moderate to severe psoriasis: results of a survey and chart review. J Eur Acad Dermatol Venereol. 2006;20:921–925.
   PubMed Web of Science ®Google Scholar
• Bridges JF, Hauber AB, Marshall D, et al. Conjoint analysis applications in health-a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value Health. 2011;14:403–413.
   PubMed Web of Science ®Google Scholar
• Schaarschmidt ML, Schmieder A, Umar N, et al. Patient preferences for psoriasis treatments: process characteristics can outweigh outcome attributes. Arch Dermatol. 2011;147:1285–1294.
   PubMed Web of Science ®Google Scholar
• Schaarschmidt ML, Umar N, Schmieder A, et al. Patient preferences for psoriasis treatments: impact of treatment experience. J Eur Acad Dermatol Venereol. 2013;27:187–198.
   PubMed Web of Science ®Google Scholar
• Schaarschmidt ML, Kromer C, Herr R, et al. Patient preferences for biologicals in psoriasis: top priority of safety for cardiovascular patients. PLoS One. 2015;10:e0144335.
   PubMed Web of Science ®Google Scholar
• Kromer C, Schaarschmidt ML, Schmieder A, et al. Patient preferences for treatment of psoriasis with biologicals: a discrete choice experiment. PLoS One. 2015;10:e0129120.
   PubMed Web of Science ®Google Scholar
• Hauber AB, Gonzalez JM, Schenkel B, et al. The value to patients of reducing lesion severity in plaque psoriasis. J Dermatolog Treat. 2011;22:266–275.
   PubMed Web of Science ®Google Scholar
• Feldman SR, Moeller AH, Erntoft Idemyr ST, et al. Relative importance of mode of administration in treatment preferences among plaque psoriasis patients in the United States. JHEOR. 2016;4:141–157.
   Google Scholar
• Blauvelt A, Gooderham M, Iverson L, et al. Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: results through 108 weeks of a randomized, phase III clinical trial (UNCOVER-3). J Am Acad Dermatol. 2017a;76:AB112.
   Google Scholar
• Blauvelt A, Reich K, Tsai TF, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: results from the CLEAR study. J Am Acad Dermatol. 2017b;76:60–69.e9.
   PubMed Web of Science ®Google Scholar
• Langley RG, Elewski BE, Lebwohl M, et al. ERASURE Study Group; FIXTURE Study Group. Secukinumab in plaque psoriasis–results of two phase 3 trials. N Engl J Med. 2014;371:326–338.
   PubMed Web of Science ®Google Scholar
• Langley RG, Lebwohl M, Krueger GG, et al.; PHOENIX 2 Investigators. Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up. Br J Dermatol. 2015;172:1371–1383.
   PubMed Web of Science ®Google Scholar
• Gordon K, Leonardi C, Braun D, et al. Results after at least 52 weeks of open label treatment with ixekizumab, an anti-IL-17A monoclonal antibody, in a phase 2 study in chronic plaque psoriasis. J Am Acad Dermatol. 2014;70:AB183.
   Web of Science ®Google Scholar
• Gordon KB, Blauvelt A, Papp KA, et al. UNCOVER-1 Study Group; UNCOVER-2 Study Group; UNCOVER-3 Study Group. phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375:345–356.
   PubMed Web of Science ®Google Scholar
• Kimball AB, Papp KA, Wasfi Y, et al.; PHOENIX 1 Investigators. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study. J Eur Acad Dermatol Venereol. 2013;27:1535–1545.
   PubMed Web of Science ®Google Scholar
• Kalb RE, Fiorentino DF, Lebwohl MG, et al. Risk of serious infection with biologic and systemic treatment of psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). JAMA Dermatol. 2015;151:961–969.
   PubMed Web of Science ®Google Scholar
• Griffiths CE, Reich K, Lebwohl M, et al. UNCOVER-2 and UNCOVER-3 investigators. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386:541–551.
   PubMed Web of Science ®Google Scholar
• Menter A, Thaçi D, Papp KA, et al. Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis. J Am Acad Dermatol. 2015;73:410–419.e6.
   PubMed Web of Science ®Google Scholar
• Secukinumab FDA prescribing information. 2018 [accessed 2019 Jul 2]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125504s001s002lbl.pdf
   Google Scholar
• Ixekizumab FDA prescribing information. 2018 [accessed 2019 Jul 2]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125521s000lbl.pdf
   Google Scholar
• Ustekinumab FDA prescribing information. 2018 [accessed 2019 Jul 2]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761044lbl.pdf
   Google Scholar
• Adalimumab FDA prescribing information. 2018 [accessed 2019 Jul 2]. Available from: https://www.fda.gov/ohrms/dockets/ac/03/briefing/3930B1_02_B-Abbott-Humira%20Prescribing%20Info.pdf
   Google Scholar
• De Bekker-Grob EW, Donkers B, Jonker MF, et al. Sample size requirements for discrete-choice experiments in healthcare: a practical guide. Patient. 2015;8:373–384.
   PubMedGoogle Scholar
• Soekhai V, de Bekker-Grob EW, Ellis AR, et al. Discrete choice experiments in health economics: past, present and future. Pharmacoeconomics. 2019;37:201–226.
   PubMed Web of Science ®Google Scholar
• Yang JC, Johnson FR, Kilambi V, et al. Sample size and utility-difference precision in discrete-choice experiments: a meta-simulation approach. J Choice Model. 2015;16:50–57.
   Web of Science ®Google Scholar
• Neidhardt K. Patient-relevant endpoints in psoriasis – a literature review of patient preference studies. Value Health. 2016;19:a571.
   Web of Science ®Google Scholar
• Eder L, Polachek A, Rosen CF, et al. The development of psoriatic arthritis in patients with psoriasis is preceded by a period of nonspecific musculoskeletal symptoms: a prospective cohort study. Arthritis Rheumatol. 2017;69:622–629.
   PubMed Web of Science ®Google Scholar
• Gottlieb A, Merola JF. Psoriatic arthritis for dermatologists. J Dermatolog Treat. 2019;24:1–18.
   Google Scholar
• Husni ME, Fernandez A, Hauber B, et al. Comparison of US patient, rheumatologist, and dermatologist perceptions of psoriatic disease symptoms: results from the DISCONNECT study. Arthritis Care Res (Hoboken). 2018; 20:102.
   Google Scholar
• Tischer B, Mehl A. Patients' and nurses' preferences for autoinjectors for rheumatoid arthritis: results of a European survey. Patient Prefer Adherence. 2018;12:1413–1424.
   PubMed Web of Science ®Google Scholar
• Johnson FR, Lancsar E, Marshall D, et al. Constructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force. Value Health. 2013;16:3–13.
   PubMed Web of Science ®Google Scholar
• Hauber AB, Gonzalez JM, Groothuis-Oudshoorn CGM, et al. Statistical methods for the analysis of discrete choice experiments: a report of the ISPOR conjoint analysis good research practices task force. Value Health. 2016;19:300–315.
   PubMed Web of Science ®Google Scholar